SEC Form SC 13G/A filed by F-star Therapeutics Inc. (Amendment)
$FSTX
Biotechnology: Pharmaceutical Preparations
Health Care
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
SCHEDULE 13G
|
Under the Securities Exchange Act of 1934
|
|
(Amendment No. 1)*
|
|
F-star Therapeutics, Inc.
|
|
(Name of Issuer)
|
|
Common Stock, par value $0.0001 per share
|
|
(Title of Class of Securities)
|
|
30315R 107
|
|
(CUSIP Number)
|
|
December 31, 2021
|
|
(Date of Event Which Requires Filing of this Statement)
|
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
☐
|
Rule 13d-1(b)
|
|
☐
|
Rule 13d-1(c)
|
|
☒
|
Rule 13d-1(d)
|
* The remainder of this cover page shall be filled out
for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
1
|
NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). |
|
|
Merck Ventures B.V.
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
|
|
(a)
|
||
|
(b) X
|
||
|
3
|
SEC USE ONLY
|
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
The Netherlands
|
||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
|
5
|
SOLE VOTING POWER
|
|
75,140
|
||
|
6
|
SHARED VOTING POWER
|
|
|
0
|
||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
75,140
|
||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
0
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
75,140
|
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
0.1%
|
|
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
|
FI
|
|
1
|
NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). |
|
|
Merck B.V.
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
|
|
(a)
|
||
|
(b) X
|
||
|
3
|
SEC USE ONLY
|
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
The Netherlands
|
||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
|
5
|
SOLE VOTING POWER
|
|
75,140
|
||
|
6
|
SHARED VOTING POWER
|
|
|
0
|
||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
75,140
|
||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
0
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
75,140
|
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
0.1%
|
|
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
|
FI
|
|
1
|
NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). |
|
|
Merck KGaA
|
||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
|
|
(a)
|
||
|
(b) X
|
||
|
3
|
SEC USE ONLY
|
|
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
Germany
|
||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
|
5
|
SOLE VOTING POWER
|
|
75,140
|
||
|
6
|
SHARED VOTING POWER
|
|
|
0
|
||
|
7
|
SOLE DISPOSITIVE POWER
|
|
|
75,140
|
||
|
8
|
SHARED DISPOSITIVE POWER
|
|
|
0
|
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
75,140
|
|
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ☐
|
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
0.1%
|
|
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
|
|
FI
|
| Item 1. | (a) | Name of Issuer |
F-Star Therapeutics, Inc.
| (b) |
Address of Issuer’s Principal Executive Offices
|
Eddeva B920
Babraham Research Campus
Cambridge, United Kingdom CB22 3AT
| Item 2. | (a) | Name of Person Filing |
This statement is filed by the following entities (collectively, referred to as the “Reporting
Persons”):
| • |
Merck Ventures B.V.
|
| • |
Merck B.V.
|
| • |
Merck KGaA
|
Merck Ventures B.V. is a wholly owned subsidiary of Merck B.V. Merck B.V. may be deemed to have sole voting and dispositive power with respect to
the shares held by Merck Ventures B.V.
Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting
and dispositive power with respect to the shares held by Merck Ventures B.V.
| (b) |
Address of Principal Business Office or, if none, Residence
|
The address of the principal business office for Merck Ventures B.V. is:
Gustav Mahlerplein 102, Toyo Ito Building, 20th Floor
1082 MA Amsterdam, The Netherlands
The address of the principal business office for Merck B.V. is:
Tupolevlaan 41-61
1119 NW Schiphol-Rijk, The Netherlands
The address of the principal business office for Merck KGaA is:
Frankfurter Straße 250
64293 Darmstadt, Germany
| (c) |
Citizenship
|
Merck Ventures B.V. is a private limited company located in the Netherlands.
Merck B.V. is a private limited company located in the Netherlands.
Merck KGaA is a German public company (Frankfurt Stock Exchange, DAX 40).
| (d) |
Title of Class of Securities
|
Common Stock, par value $0.0001 per share
| (e) |
CUSIP Number
|
30315R 107
| Item 3. |
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
Not applicable.
| Item 4. |
Ownership.
|
(a) Amount beneficially owned:
See Row 9 of cover page for each Reporting Person.
(b) Percent of class:
See Row 11 of cover page for each Reporting Person.
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Row 5 of cover page for each Reporting Person.
(ii) Shared power to vote or to direct the vote:
See Row 6 of cover page for each Reporting Person.
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of cover page for each Reporting Person.
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for each Reporting Person.
| Item 5. |
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the
beneficial owner of more than 5 percent of the class of securities, check the following ý.
| Item 6. |
Ownership of More than Five Percent on Behalf of Another Person.
|
Not applicable.
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
|
Not applicable.
| Item 8. |
Identification and Classification of Members of the Group.
|
Not applicable.
| Item 9. |
Notice of Dissolution of Group.
|
Not applicable.
| Item 10. |
Certification.
|
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 8, 2022
MERCK VENTURES B.V.
By: /s/ Hakan Goker
Name: Hakan Goker
Title: Managing Director
By: /s/ Owen Lozman
Name: Owen Lozman
Title: Managing Director
MERCK B.V.
By: /s/ Spasena Ivanova Yotova
Name: Spasena Ivanova Yotova
Title: Managing Director
By: /s/ Saraswati Khan
Name: Saraswati Khan
Title: Managing Director
MERCK KGAA
By: /s/ Rando Bruns
Name: Rando Bruns
Title: Head of Treasury
By: /s/ Johannes Eckhardt
Name: Johannes Eckhardt
Title: Corporate Counsel
Strategic Participations & Corporate Affairs